Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Boston Scientific wins battle for Guidant
The victory for Boston will give the company access to the cardiovascular device market said to be worth in excess of $10 billion. Analysts predict that J&J will
The victory for Boston will give the company access to the cardiovascular device market said to be worth in excess of $10 billion. Analysts predict that J&J will
Based on this phase II dose-ranging study and in line with the company’s product development strategy to best prepare for its phase III study, Nabi will next conduct
The phase I clinical trial of oral KOS-1022 will evaluate the safety, pharmacokinetics, pharmacodynamics, and bioavailability of escalating doses of the drug in patients with advanced solid tumors,
The study will be conducted at approximately 15 centers in the US, and is expected to enroll patients with advanced or metastatic breast cancer who have failed conventional
These agreements include new partnerships and extensions to old agreements with CeNes, Gemin X Biotechnologies, Genzyme Corp, GlaxoSmithKline R&D, and Schering-Plough Research Institute. The agreements were all finalized
The grant comes from the Lyon Biopole Competitiveness Cluster (pole de competitivite), a French government scheme designed to promote industrial growth in the country. This funding is expected
In the collaboration ImQuest will provide complete preclinical and clinical drug development support for therapeutic small molecules discovered by Samjin Pharmaceutical. “This relationship merges the significant individual strengths
The company says that it is deploying the majority of its resources to identify the clinical utility of tgAAC94 and will also continue to utilize its development and
Significantly more elderly patients treated with the Bayer drug Avelox (moxifloxacin HCl) for community-acquired pneumonia (CAP) recovered at days three to five of a seven to 14 day
In December 2003 Array partnered the oncology portion of its MEK program, including its lead compound, ARRY-142886, for co-development and commercialization with AstraZeneca. At that time, Array and